Oral hyaluronic acid
Promising · 3 studies cited · 2 min · Updated 2026-08-14
In short: Swallowed hyaluronic acid at 80–240 mg/day has placebo-controlled trials reporting knee-symptom relief — but the flagship 12-month RCT was authored by employees of an HA manufacturer, its headline result is an age-subgroup finding, and a 13-for-13 positive trial record in small studies is a textbook publication-bias signature. Do not transfer confidence from HA injections.
Hyaluronic acid is a major component of synovial fluid and cartilage matrix, which makes swallowing it feel intuitive. The intuition doesn't survive pharmacology: intact high-molecular-weight HA is barely absorbed, so a direct "replenishment" story is implausible. The proposed mechanisms are indirect — gut-receptor signalling (TLR4/CD44 binding by HA fragments) with downstream anti-inflammatory effects, and stimulation of the body's own HA synthesis — partly demonstrated in animal models, not in humans. Marketing claims about molecular weight ("low MW absorbs better") outrun the evidence in both directions.
The trials
Tashiro 2012 is the longest and most cited: 60 Japanese adults with knee OA took 200 mg/day of high-molecular-weight HA or placebo for 12 months, with both groups doing daily quadriceps exercise. Symptom scores (JKOM) improved more with HA — but the difference reached significance mainly in the subgroup aged 70 or younger, in a 60-person trial with an exercise co-intervention. The authors are employees of Kewpie Corporation, an HA manufacturer.
Kalman 2008 is the closest thing to independent US data: a 20-person pilot of a chicken-comb extract (80 mg/day) over 8 weeks, with numerically better WOMAC pain and quality-of-life changes that mostly failed to reach significance — honestly framed by its authors as hypothesis-generating.
The field's main review counts 13 human trials, all positive, at 80–240 mg/day. That review was written by the same Kewpie-affiliated group. Thirteen for thirteen in small sponsor-run studies says as much about who runs and publishes these trials as about the molecule.
What this is not
Evidence for oral HA is categorically weaker than for intra-articular HA injections — different route, different literature, different confidence. Readers should not let the injection data launder the supplement. There are no structural outcomes, no large independent trial, and nothing prominent registered. Combination products (HA + collagen + chondroitin) dominate retail shelves, and attributing benefit within those blends is impossible.
Dose & practical notes
Trialed doses run 80–240 mg/day, with 200 mg/day for 12 months in the flagship study. Where effects were reported, they accrued over months, not weeks. Products vary in source (microbial fermentation versus rooster comb) and molecular weight; no clinical data establish superiority of any format, whatever the label argues.
Safety
No safety signals in trials up to 12 months. HA is a normal dietary and endogenous molecule, and adverse events matched placebo. Theoretical concerns raised about HA in tumor biology have no clinical supplement data behind them, and there are no established drug interactions.
What I take from it
The trials exist, they point the same way, and the molecule is safe — which is why this sits in promising rather than lower. But the entire evidence base has a manufacturer's fingerprints on it, the best trial's headline is a subgroup, and the one independent-feeling study was too small to conclude anything. An independent, adequately powered trial would settle this; no one selling HA seems in a hurry to run it.
Why this tier? Promising at the weak end: placebo-controlled trials exist and report benefit, but nearly the entire literature — including the flagship 12-month RCT (n=60) and the field's main review — is authored by employees of HA manufacturers, trials are small, and the best-known finding is a subgroup result in participants aged 70 or younger.